Tiziana Life Sciences Ltd
TLSA
1.05 $
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer TLSA
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Aktuelle News
-
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Vorschau anzeigen
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch...
-
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Vorschau anzeigen
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m.
-
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Vorschau anzeigen
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding
-
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Vorschau anzeigen
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment. The...
-
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Vorschau anzeigen
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing. Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinical